4/A: Revolution Medicines Director Alexis Borisy Corrects Stock Option and RSU Award Amounts in Amended SEC Filing

Alexis Borisy, a director at Revolution Medicines, filed an amended SEC Form 4 to correct previously reported amounts for restricted stock units (RSUs) and stock options granted on June 20, 2024.

Summary

• Revolution Medicines director Alexis Borisy filed an amended SEC Form 4/A on June 28, 2024, to correct inaccuracies in a previous filing from June 24, 2024.
• The amendment addresses errors in the reported amounts for restricted stock units (RSUs) and stock options granted to Borisy on June 20, 2024.
• The corrected filing shows Borisy was granted 4,248 RSUs and 15,955 stock options.
• Borisy directly owns 2,335,742 shares of Revolution Medicines common stock, including the RSUs.
• The stock options have an exercise price of $37.54 and will vest on the earlier of June 20, 2025, or immediately before the company's next annual meeting, contingent on continued service.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previous filing, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it reflects transparency and adherence to regulatory requirements.

Future Outlook

The stock options vest on the earlier of June 20, 2025, or immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry. It provides transparency into the equity-based incentives for key personnel at Revolution Medicines.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices for directors and executives in publicly traded biotechnology companies like Revolution Medicines.
• Companies such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation to align management's interests with those of shareholders.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to incentivize long-term performance and retention.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders regarding executive compensation and ownership.
• This promotes transparency and trust in the company's governance practices.

Key Dates